Category Archives: Stell Cell Research


Stem Cell Research: Uses, Types & Examples

Stem cells are undifferentiated, or blank, cells. This means theyre capable of developing into cells that serve numerous functions in different parts of the body. Most cells in the body are differentiated cells. These cells can only serve a specific purpose in a particular organ. For example, red blood cells are specifically designed to carry oxygen through the blood.

All humans start out as only one cell. This cell is called a zygote, or a fertilized egg. The zygote divides into two cells, then four cells, and so on. Eventually, the cells begin to differentiate, taking on a certain function in a part of the body. This process is called differentiation.

Stem cells are cells that havent differentiated yet. They have the ability to divide and make an indefinite number of copies of themselves. Other cells in the body can only replicate a limited number of times before they begin to break down. When a stem cell divides, it can either remain a stem cell or turn into a differentiated cell, such as a muscle cell or a red blood cell.

Since stem cells have the ability to turn into various other types of cells, scientists believe that they can be useful for treating and understanding diseases. According to the Mayo Clinic, stem cells can be used to:

There are several types of stem cells that can be used for different purposes.

Embryonic stem cells come from human embryos that are three to five days old. They are harvested during a process called in-vitro fertilization. This involves fertilizing an embryo in a laboratory instead of inside the female body. Embryonic stem cells are known as pluripotent stem cells. These cells can give rise to virtually any other type of cell in the body.

Adult stem cells have a misleading name, because they are also found in infants and children. These stem cells come from developed organs and tissues in the body. Theyre used by the body to repair and replace damaged tissue in the same area in which they are found.

For example, hematopoietic stem cells are a type of adult stem cell found in bone marrow. They make new red blood cells, white blood cells, and other types of blood cells. Doctors have been performing stem cell transplants, also known as bone marrow transplants, for decades using hematopoietic stem cells in order to treat certain types of cancer.

Adult stem cells cant differentiate into as many other types of cells as embryonic stem cells can.

Scientists have recently discovered how to turn adult stem cells into pluripotent stem cells. These new types of cells are called induced pluripotent stem cells (iPSCs). They can differentiate into all types of specialized cells in the body. This means they can potentially produce new cells for any organ or tissue. To create iPSCs, scientists genetically reprogram the adult stem cells so they behave like embryonic stem cells.

The breakthrough has created a way to de-differentiate the stem cells. This may make them more useful in understanding how diseases develop. Scientists are hoping that the cells can be made from someones own skin to treat a disease. This will help prevent the immune system from rejecting an organ transplant. Research is underway to find ways to produce iPSCs safely.

Cord blood stem cells are harvested from the umbilical cord after childbirth. They can be frozen in cell banks for use in the future. These cells have been successfully used to treat children with blood cancers, such as leukemia, and certain genetic blood disorders.

Stem cells have also been found in amniotic fluid. This is the fluid that surrounds a developing baby inside the mothers womb. However, more research is needed to help understand the potential uses of amniotic fluid stem cells.

Adult stem cells dont present any ethical problems. However, in recent years, there has been controversy surrounding the way human embryonic stem cells are obtained. During the process of harvesting embryotic stem cells, the embryo is destroyed. This raises ethical concerns for people who believe that the destruction of a fertilized embryo is morally wrong.

Opponents believe that an embryo is a living human being. They dont think the fertilized eggs should be used for research. They argue that the embryo should have the same rights as every other human and that these rights should be protected.

Supporters of stem cell research, on the other hand, believe that the embryos are not yet humans. They note that researchers receive consent from the donor couple whose eggs and sperm were used to create the embryo. Supporters also argue that the fertilized eggs created during in-vitro fertilization would be discarded anyway, so they might be put to better use for scientific research.

With the breakthrough discovery of iPSCs, there may be less of a need for human embryos in research. This may help ease the concerns of those who are against using embryos for medical research. However, if iPSCs have the potential to develop into a human embryo, researchers could theoretically create a clone of the donor. This presents another ethical issue to take into consideration. Many countries already have legislation in place that effectively bans human cloning.

In the United States, federal policy regarding stem cell research has evolved over time as different presidents have taken office. Its important to note that no federal regulation has ever explicitly banned stem cell research in the United States. Rather, regulations have placed restrictions on public funding and use. However, certain states have placed bans on the creation or destruction of human embryos for medical research.

In August 2001, former President George W. Bush approved a law that would provide federal funding for limited research on embryonic stem cells. However, such research had to fit the following criteria:

In March 2009, President Barack Obama revoked former President Bushs statement and released Executive Order 13505. The order removed the restrictions on federal funding for stem cell research. This allowed the National Institutes of Health (NIH) to begin funding research that uses embryonic stem cells. The NIH then published guidelines to establish the policy under which it would fund research. The guidelines were written to help make sure that all NIH-funded research on human stem cells is morally responsible and scientifically relevant.

Stem cell research is ongoing at universities, research institutions, and hospitals around the world. Researchers are currently focusing on finding ways to control how stem cells turn into other types of cells.

A primary goal of research on embryonic stem cells is to learn how undifferentiated stem cells turn into differentiated stem cells that form specific tissues and organs. Researchers are also interested in figuring out how to control this process of differentiation.

Over the years, scientists have developed methods to manipulate the stem cell process to create a particular cell type. This process is called directed differentiation. A recent studyalso discovered the first steps in how stem cells transform into brain cells and other types of cells. More research on this topic is ongoing.

If researchers can find a reliable way to direct the differentiation of embryonic stem cells, they may be able to use the cells to treat certain diseases. For example, by directing the embryonic stem cells to turn into insulin-producing cells, they may be able to transplant the cells into people with type 1 diabetes.

Other medical conditions that may potentially be treated with embryonic stem cells include:

Californias Stem Cell Agency provides a detailed list of the disease programs and clinical trials currently underway in stem cell research. Examples of such projects include:

Researchers are also using differentiated stem cells to test the safety and effectiveness of new medications. Testing drugs on human stem cells eliminates the need to test them on animals.

Stem cell research has the potential to have a significant impact on human health. However, there is some controversy around the development, usage, and destruction of human embryos. Scientists may be able to ease these concerns by using a new method that can turn adult stem cells into pluripotent stem cells, which can change into any cell type. This would eliminate the need for embryonic stem cells in research. Such breakthroughs show that much progress has been made in stem cell research. Despite these advancements, theres still a lot more to be done before scientists can create successful treatments through stem cell therapy.

Read the original post:
Stem Cell Research: Uses, Types & Examples

Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News – Dagoretti News

About global Stem Cell Assay market

The latest global Stem Cell Assay market study is an in-depth and professional assessment of the current situation of the global Stem Cell Assay industry, including market size, revenue, pricing, trends, and future prospects. According to the report, the global Stem Cell Assay market pegged a value of ~US$ xx Mn/Bn in 2018 and is expected to progress at a CAGR of xx% during the foreseeable timeframe 2019-2029.

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=19364

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report answers some of the important questions, including:

The report provides the following data:

Buy reports at discount prices!!!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report presents accurate and up-to-date insights regarding the Stem Cell Assay market from trusted suppliers, service providers, and value chain partners via extensive primary and secondary research. The information regarding each market vendor includes company background, main market insight, SWOT analysis, sales, revenue, pricing and gross margin, and market share.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Mr. Rohit BhiseyTransparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

Read more:
Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News - Dagoretti News

2D Cell Culture Market to Witness Growth Acceleration During 2020 to 2026 Dagoretti News – Dagoretti News

Global Marketers.biz offers newly published a research report titled, Global 2D Cell Culture Market Research Report 2020. Primary and secondary research methodologies have been used to formulate this report. The analysis has been derived using historic and forecast. The industry is expected to thrive in terms of volume and value during the forecast years. This report offers an understanding of various drivers, threats, opportunities, and restraints in the market. Analysts have used SWOT and Porters five forces analysis to determine the effect these factors will have on the market growth during the forecast period. The 2D Cell Culture industry report includes in-depth examination of geographical regions, revenue forecasts, segmentation, and market share.

For More Details, Get a Sample Copy of This Report (Including Full TOC, Table & Figures) @: https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #request_sample

Key players profiled in the report on the global 2D Cell Culture Market are:

Emd MilliporeCedarlane LaboratoriesATCCAbcamBiolaminaThermo Fisher ScientificBecton DickinsonBio-Techne3PbioIbdiCell Guidance SystemsMerck MilliporeCorningBiomedtech LaboratoriesGE Life ScienceCell Culture CompanyCellsystemsGreiner Bio-One International AgSigmaaldrichSigma-Aldrich

Global 2D Cell Culture Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global 2D Cell Culture Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the global 2D Cell Culture market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global 2D Cell Culture Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The global 2D Cell Culture market is segmented

on the basis of product type, applications, and its end users.

Global 2D Cell Culture Market by Type:

SkinLungBrainKidneyLiverBreastOthers

Global 2D Cell Culture Market by Application:

PharmaceuticalStem Cell ResearchComparative Genome SequencingBioproductionFood ApplicationBioenergyEnvironment Testing and ToxicologyAgriculture

Global 2D Cell Culture Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, Europe, Asia Pacific, and the Middle East and Africa.

2D Cell Culture Market Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #inquiry_before_buying

In this study, the years considered to estimate the market size of Network Traffic Analysis Software are as follows:

Highlights of TOC:

Executive Summary: The report starts with an easy-to-read, easy-to-understand summary of the entire market research study to help readers to gain quick understanding of the global 2D Cell Culture market.

Company Profiles: This section provides key details about the business and market growth of leading players of the global 2D Cell Culture market.

Market Dynamics: The report offers comprehensive analysis of key growth drivers, restraints, trends, and opportunities of the global 2D Cell Culture market.

Market Forecasts: Here, the report offers accurate market size forecasts for the global 2D Cell Culture industry, its segments and sub-segments, and all regions considered for the study.

Recommendations: Market recommendations provided in the report are very specific and research-backed. They have been created to help players move in the right direction during their journey to achieve success in the global 2D Cell Culture market.

Explore Full 2D Cell Culture Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/global-2d-cell-culture-market-report-2019,-competitive-landscape,-trends-and-opportunities/133394 #table_of_contents

We Also Offer Customization on report as per clients specific Requirement:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad ([emailprotected]).

For more relevant information visit @ https://www.globalmarketers.biz

Read the original post:
2D Cell Culture Market to Witness Growth Acceleration During 2020 to 2026 Dagoretti News - Dagoretti News

Stem Cell and Progenitor Cell-based therapeutics Market 2020 Share Growing Rapidly with Recent Trends, Growth, Size, Share, Clinical Review,…

Download Sample Copy of the Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Market Analysis and Insights of Global Stem Cell and Progenitor Cell-based Therapeutics Market-Stem cell & progenitor cell-based therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 9.4% in the above-mentioned forecast period. Increasing focus on stem research is anticipated to create new opportunity for the stem cell & progenitor cell based therapeutics market. Development policies and plans are discussed as well as companies processes and cost structures are also analyzed in this Stem Cell and Progenitor Cell-based Therapeutics report. This Stem Cell and Progenitor Cell-based Therapeutics report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin Stem Cell and Progenitor Cell-based Therapeutics by regions (North America, Europe, Asia Pacific, Middle East & Africa, Latin America), and other regions can be added.

The Major KEY PLAYERS Influence the GlobalStem Cell and Progenitor Cell-based Therapeutics MarketareVitroBioPharma, ViaCyte, Inc., Vericel., U.S. Stem Cell, Inc., Stemedica Cell Technologies, Inc., ReNeuron Group plc, Osiris, Juventas Therapeutics, Gamida Cell., Epistem Ltd., DAIICHI SANKYO COMPANY, LIMITED., Cytori Therapeutics Inc., Cellerant Therapeutics, Inc, among other domestic and global players.

The report motivates the clients by providing a basic overview of the Stem Cell and Progenitor Cell-based Therapeutics industry along with the definition of the product, product price and cost structure, classifications, leading competitive players with classifications. Further, the elaborate the manufacturing process of the Stem Cell and Progenitor Cell-based Therapeutics products, supply-demand ratio, capacity utilization, market profit and product requirements along with growth estimation.

Competitive Landscape and Stem Cell and Progenitor Cell-based Therapeutics Market Share Analysis

Stem Cell and Progenitor Cell-based Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Stem Cell and Progenitor Cell-based Therapeutics market.

Share Your Query Before Purchasing This Report@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Global Stem Cell & Progenitor Cell-Based Therapeutics Market Scope and Market Size

Some of the key geographies mentioned in this report include:

Global Stem Cell & Progenitor Cell-based therapeutics Market Report Focus:

Latest technological developments

Value chain analysis

Potential Stem Cell & Progenitor Cell-based therapeutics Market opportunities

Extensive product offerings

Customer research services

Robust research methodology

Comprehensive reports

Growth dynamics

Quality assurance

Post-sales support

Regular report updates

Purchase this Report (Single User Access) @https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-stem-cell-and-progenitor-cell-based-therapeutics-market

Reasons to Purchase this Report:

Table of Content: Global Security Labels Marketss

TOC Continued

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 74ss75

Email:[emailprotected]

Read more:
Stem Cell and Progenitor Cell-based therapeutics Market 2020 Share Growing Rapidly with Recent Trends, Growth, Size, Share, Clinical Review,...

Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News – Dagoretti News

Latest Report on the Animal Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study that offers critical insights related to the growth prospects of the Animal Stem Cell Therapy Market during the forecast period 2017 2025. The report takes into account the historical and current market trends to evaluate the top factors that are likely to influence the growth of the market in the upcoming years.

As per the report, the Animal Stem Cell Therapy Market is poised to grow at a CAGR of ~XX% during the assessment period primarily driven by a growing focus on product innovation, a surge in demand for the Animal Stem Cell Therapy in the developed regions, and potential opportunities in the developing regions.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

Essential findings of the report:

The report aims to address the following queries related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

What Sets Us Apart From the Rest?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

Read more here:
Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News - Dagoretti News

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies – Yahoo…

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -

- Agreement leverages Astellas Universal Donor Cell Platform and Adaptimmunes stem-cell derived allogeneic T-cell platform -

- Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products -

TOKYO, PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.

Adaptimmune has been collaborating with Universal Cells (now an Astellas Company) since 2015 on development of gene-edited iPSC cell lines, for which Adaptimmune has rights to develop and commercialize resulting T-cell therapy products using its proprietary process for generating T-cells from stem cells without the use of feeder cell lines.

Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.

"Astellas positions immuno-oncology as one of its strategic areas of primary focus, and it is engaged in the development of novel therapies for cancer patients using a new modality/technology," stated Naoki Okamura, Representative Director Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer, Astellas. "In addition to NK cells, T-cells are an important component of cell therapy for immuno-oncology, and we look forward that this agreement with Adaptimmune will enable us to create new stem-cell derived allogeneic T-cell therapies for a variety of cancers, including solid tumors, in the future. We will continue to dedicate our efforts in delivering novel treatments for diseases with high unmet medical needs, pursuing cutting-edge science and technological advances.

We are delighted to establish this significant co-development partnership with Astellas, which builds upon and substantially extends an existing collaboration focused on gene editing of iPSC cells, said Helen Tayton-Martin, Adaptimmunes Chief Business Officer and Co-Founder. This new collaboration may encompass both CAR-T and TCR T-cell approaches, including our novel HLA-independent TCR (HiT) platform. It brings together highly complementary skills and expertise across the two organizations, and will enable the accelerated development of new, off-the-shelf T-cell therapy products for people with cancer.

Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.

Story continues

Under the terms of the agreement, Adaptimmune may receive up to $897.5 million in payments, including:

In addition, Adaptimmune will receive research funding of up to $7.5 million per year.

Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Under the terms of the agreement, Astellas may receive up to $552.5 million, including:

In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.

To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.

The impact of this transaction on Astellas financial results in the fiscal year ending March 31, 2020 will be limited.

About AdaptimmuneAdaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Companys unique SPEAR (Specific Peptide Enhanced Affinity Receptor) Tcell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.

About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en

Adaptimmune Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Cautionary Notes Regarding Forward-Looking Statements (Astellas)In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on managements current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Adaptimmune Contacts:

Media Relations:Sbastien Desprez VP, Communications and Investor RelationsT: +44 1235 430 583M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.com

Investor Relations: Juli P. Miller, Ph.D. Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com

Contacts for inquiries or additional information:Astellas Pharma Inc.Corporate CommunicationsTEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Read the original here:
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies - Yahoo...

Universities aren’t making a lot of money from university research – The Hechinger Report

The Hechinger Report is a national nonprofit newsroom that reports on one topic: education. Sign up for our weekly newsletters to get stories like this delivered directly to your inbox.

Stanford Medical School Professor Daria Mochly-Rosen delivers a TEDMED talk about how, frustrated by the slow process of bringing to market a drug that she discovered, she founded an international organization to help speed up the transformation of academic research into usable products. Photo: TEDMED/YouTube

When Daria Mochly-Rosen discovered a compound in her lab that promised to lessen the effects of heart attacks, she set out to convince pharmaceutical companies to develop it.

She couldnt.

So the professor of chemistry and systems biology at Stanford Universitys School of Medicine took a leave of absence and started her own company to further test and potentially commercialize the drug.

It seemed the obvious next step. After all, universities often speak of their success in turning research into products that make life better, with the added bonus of contributing to the economy. There are seemingly countless examples, from Gatorade, invented at the University of Florida, to Google, which began at Stanford; and from web browsers and plasma screens, both created at the University of Illinois, to the drug that became the allergy medicine Allegra, developed at Georgetown University.

But Mochly-Rosen quickly learned that there were myriad obstacles standing in the way of those kinds of payoffs, which turned out to be more exceptions than rules.

Other universities look at those very few rare cases and imagine they can also hit the invention jackpot, she said. But academicians are absolutely clueless about what needs to be done to make a project attractive to industry.

For those and other reasons, and at a time when they would seem to be searching for new sources of revenue, U.S. colleges and universities are producing a surprisingly small proportion of the nations patents and startups and making so little money from licensing inventions that, at many schools, it doesnt even cover the cost of managing them.

Most of the $75.3 billion a year from the federal government and other sources that the National Science Foundation calculates is spent by academia on research is not intended to immediately result in commercial applications. Its about fundamental knowledge. The basic research performed in university laboratories underpins discoveries that may take years to end up in the market, if they ever do.

But higher education itself often draws a connection between its research and financial returns, as it did in December after Congress increased annual research funding by $2.6 billion. The money will enhance U.S. global competitiveness [and] national security and lead to innovations that grow our economy while improving quality of life, the Association of Public and Land-grant Universities proclaimed.

Trying to prod more commercialization of discoveries from federally sponsored research is also why, 40 years ago this year, Congress passed the Bayh-Dole Act, which gave universities the rights to the licensing revenue resulting from their research.

In fact, academic institutions accounted for only 6,639 of the 304,126 patents granted in 2016, the last year for which the figure is available, or 2 percent of the total, according to the National Science Board, which described patenting by academic inventors as being relatively limited.

When you look at university PR offices, they always talk about how theres this new research coming out of some department, and its going to revolutionize the economy, said Lee Vinsel, an assistant professor of science, technology and society at Virginia Tech who is co-authoring a forthcoming book called The Innovators Delusion. But, he said, weve been overestimating the role were playing.

Marc Levine, emeritus professor of history, University of Wisconsin-Milwaukee

Universities and colleges spun off 11,000 startups between 1996 and 2015 an average of 550 per year according to the Association of University Technology Managers, or AUTM, whose members oversee what is known as technology transfer. Thats one-tenth of 1 percent of the roughly 400,000 annual startups reported by the Bureau of Labor Statistics.

It has almost become de rigueur among chancellors and presidents in selling the value of their universities to the larger community to say that we are engines of economic development, and theres scant evidence to support that, said Marc Levine, an emeritus professor of history at the University of Wisconsin-Milwaukee who has studied this subject.

The economic development argument is tenuous at best and probably even less than tenuous, Levine said.

Related: Panicked universities in search of students are adding thousands of new majors

Now some institutions are redoubling their efforts to smooth the way for their discoveries to be shared and sold.

Thats increasingly important, and not only because universities and colleges are facing state budget cuts, enrollment declines and other financial challenges. The federal portion of funding for university research has also been steadily declining, forcing institutions to look for other sources of support. And money that comes from licensing typically goes back into the research budget.

There is a real sense of urgency generally to find new ways of underwriting university research, said Joseph Allen, who as a staffer to Senator Birch Bayh helped steer the Bayh-Dole Act and later served as director of technology commercialization in the Commerce Department. The public is expecting, Youve been entrusted with billions of dollars in government research. We want to see results.

Related: Some colleges seek radical solutions to survive

But moving research from a lab to the market is complex. First, researchers have to be willing to invest time in translating abstract concepts into tangible products. Many arent, technology-transfer directors said. One called it the unbaked cake phenomenon: Academic researchers show up in her office with a metaphorical bag of flour and a cup of sugar, she said, when what investors and potential partners want is a fully baked cake.

Joseph Allen, former director of technology commercialization in the Commerce Department

Mochly-Rosen said she has seen this among her colleagues and counterparts. Theyre saying, This is as far as I want to take it, and someone else can take it from there.

After all, faculty are awarded tenure and promotion based on measures such as how much research money they bring in and how many papers they publish, not their numbers of patents or startups or the licensing revenue they earn. Even the profits from commercialization, which most universities share with them, prove little motivation.

Thats because the process takes so long. Getting a patent can take five to seven years, said Allen, and testing a drug or developing a product even longer than that. Many fail, falling into what investors call the valley of death of abandoned ideas.

Its a high-risk, imprecise thing, he said.

People think inventions come pouring out of universities. But you have to find somebody willing to pay money for it, license it, develop it. Theres a lot of steps there that are out of your control, and we should be realistic about that. It doesnt mean we cant do better.

Some universities are trying. Theyre responding not only to the potential financial benefits, but to prodding from their own faculty, or from the government agencies that fund them. And that annual number of patents, while still low, has begun to rise.

After her rocky experience with the compound she developed that aids heart-attack recovery, Mochly-Rosen founded an organization called SPARK to speed up the transformation of academic discoveries into FDA-approved drugs and treatments.

Related: As college enrollment falls, recruiters descend on a state that still has lots of applicants

SPARK does this by bringing in volunteer experts from industry to help train faculty and students about how to bring the results of their research to market, and by giving them $50,000 a year for two years to create product proposals, also known as proofs of concept.

The Stanford University campus. Though a leader in converting discoveries from research into commercial products, Stanford is among several universities revamping this process to realize a higher return. Photo: Justin Sullivan/Getty Images

Sixty-two percent of SPARK projects are in clinical trials or have been licensed to new or existing companies or transferred to industry, a case study found, a much higher proportion than occurs with academic research discoveries in general. Now the model has spread to more than 60 universities and colleges in 22 countries.

To do good is first and foremost our agenda, said Mochly-Rosen, who has since established two more startups. Were benefitting from the taxpayers money to do research. Its our social responsibility. As for doing well, it is a very expensive business to develop drugs. So we have to recognize that you need money in order to make money, and its not incongruent with the agenda of social good.

Stanford also has reorganized its Office of Technology Licensing, under a new director who began in mid 2018, centralizing its functions and hiring new business development staff. The goal, it said, is to realize a higher return on our marketing efforts.

Its paying off. Already acknowledged to be a leader in this field, Stanford reported 560 invention disclosures and 150 licensing agreements in 2018, all up significantly over five years.

Theres a trend to push those numbers higher, said Brooke Beier, vice president for technology commercialization at the Purdue Research Foundation.

Related: Students, employees scour college finances for waste, proof of unfair pay

At her university, said Beier, who was also appointed to her job in mid 2018, The leadership and faculty inventors are making a focused effort to convert more research findings into products.

The number of patent applications is up 42 percent at Purdue over the last five years, to more than 670 last year, while the number of licensing deals rose 13 percent and the number of invention disclosures formal determinations that a discovery may be worthy of a patent increased 32 percent, to 360.

We are a university that focuses on research. Were not a product development company. But at the same time we do a lot of applied research and want to translate that to the market, Beier said.

Even the university that receives the most research funding in the nation, Johns Hopkins, did some soul searching when faculty who were trying to commercialize their findings complained about a lack of institutional resources being made available to do that. Its $1.5 billion of research in 2012, a resulting investigation found, produced less than $16 million in licensing fees, about one-tenth as much as rivals including Columbia and MIT. There was no mentorship or funding to encourage licensing or startups, and technology transfer efforts were fragmented.

Johns Hopkins University. Despite conducting $1.5 billion worth of research at the time, an investigation in 2012 found that Hopkins was producing less than $16 million a year from licensing, about one-tenth as much as rivals Columbia and MIT. Photo: Carol M. Highsmith/Buyenlarge/Getty Images

There, too, the process has been revamped, with the creation of Johns Hopkins Technology Ventures, or JHTV. The university says it has now pulled ahead of Harvard, MIT, Columbia and Stanford in the number of new licenses its entered into and is tied for fourth in the number of startups.

There was a lot of untapped commercial potential, said Christy Wyskiel, JHTVs executive director, who was brought in from the private sector to run the effort. The type of research that happens here is really second to none. The question became, Why, from a job-creation or a licensing-revenue perspective, were we also not at the top? This ought to be a major part of our mission.

The University of California, Riverside, has also streamlined its technology-transfer functions, receiving 42 patents last year its most ever and attracting a 10 percent increase in direct corporate research funding: $16 million.

One way its done this is by spending money to make money, giving $1.4 million so far to researchers who want to show proof of concept, which technology transfer administrators say government grants typically dont cover. Other universities, including the University of Chicago, have created their own multimillion-dollar funds to invest in early stage faculty startups.

Our main objective is, yes, we want to get a return, said Brian Suh, director of Riversides Office of Technology Partnerships. But first we want to know, are they really going to be able to take this technology and bring it to market, which is a win-win for both sides.

Related: As small private colleges keep closing, some are fighting back

The National Science Foundation is trying to further speed up this process with a program called Innovation Corps, which trains researchers in how to commercialize work that was funded by the NSF. Its so far resulted in 644 startup companies, the agency says.

Stephen Susalka, CEO of AUTM, likened the need for this extra effort to the shift from employers once being willing to hire workers with only high school diplomas. Now more jobs require a degree, he said.

A researcher uses a microscope to look at stem cells at the Lokey Stem Cell Research Building at Stanford University. Stanford reported 560 invention disclosures and 150 licensing agreements in 2018, all up significantly over five years. Photo: John Green/Bay Area News Group/MediaNews Group/Bay Area News via Getty Images

Its kind of the same with technology transfer, said Susalka, former associate director for commercialization at Wake Forest University. Back when I started we could identify a device that might be useful, file a patent application and license that intellectual property. Now you need to develop that invention further than a purely academic researcher might do, so youre starting to see more tech transfer offices have a prototyping fund. Youre seeing more universities have venture funds to support those early stage startups.

Even the institutions where this work is getting more attention serve as examples of how long it takes to see returns, and how small they seem in comparison to the dollar value of the research they do.

Purdue conducted $645 million in research last year, from which it earned $6.7 million after costs were deducted.

Powerhouse Stanford earned $41 million in 2018 in royalties from licenses that emerged from university research. Legal expenses and administrative costs consumed more than a third of that, leaving $25.6 million to be divided among researchers and their departments. This at an institution with an $11.6 billion annual budget, including $1.7 billion a year in sponsored research.

Lee Vinsel, assistant professor of science, technology and society, Virginia Tech

One of the technologies licensed by Stanford earned just $11 in 2018, and 760 made less than $100,000 each. Only seven cleared $1 million or more.

Most universities make even less.

Twenty-nine of the 187 research institutions that reported their activity to AUTM collected less than $100,000 apiece in licensing revenue in 2017, the last year for which the figures are available, according to an analysis of the data by The Hechinger Report. Just 15 accounted for 72 percent of all the money. And the top five alone earned more than half. The list includes some academic medical centers and university-affiliated research hospitals.

Its a bit like college football, Levine said: There are some big-time programs that make a lot of money. There are some winners in the tech transfer, commercialization-of-research game, but those tend to be fairly few and far between.

Another way a few universities are trying to maximize their income is by becoming more aggressive in protecting their existing patents, something theyve previously been reluctant to do because there wasnt any money in their budgets for it. The University of California system in July sued Walmart, Ikea, Target and other retailers for the unauthorized sale of light bulbs with LED filament technology developed at UC Santa Barbara. The suit is being underwritten by a litigation financing fund in exchange for a portion of any award that results.

The enforcement work is part of that broader evolution of technology transfer, said Seth Levy, lead attorney in the case, which is pending. The trick is in making sure that the university gets some reasonable share of the proceeds when this technology is brought to market.

In one of the more unusual enforcement attempts, the University of Florida pursued the $2 million won in an artificial intelligence competition by two of its professors and four students. Unless the winners turned over the money, a university lawyer wrote, they would be subject to personnel action and possibly other more serious consequences. That move was reversed after the faculty union filed unfair labor practices complaints.

At most universities, despite all of this effort, said Virginia Techs Vinsel, the flow of money from discoveries remains a comparative trickle.

Theres always reform around this stuff. Theres always, Heres the new way were going to do it, he said.

I dont want to be overly skeptical. But theres a long track record of trying different things and not succeeding as much as the boosters have hyped it.

This story about university research was produced by The Hechinger Report, a nonprofit, independent news organization focused on inequality and innovation in education. Sign up for our higher education newsletter.

Join us today.

Go here to read the rest:
Universities aren't making a lot of money from university research - The Hechinger Report

R&D Activities to Fast-track the Growth of the Biobanks Market Between 2017 2025 Dagoretti News – Dagoretti News

Biobanks Market (2019) Report Provides an in-depth summary of Biobanks Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Biobanks Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Biobanks market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Biobanks market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321&source=atm

Leading manufacturers of Biobanks Market:

Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=2321&source=atm

Scope of The Biobanks Market Report:

This research report for Biobanks Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Biobanks market. The Biobanks Market Report analyzes opportunities in the overall Biobanks market for stakeholders by identifying the high-growth segments.

A detailed overview of the geographical and competitive sphere of the Biobanks market:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=2321&source=atm

Table of Content of The Report

Chapter 1- Biobanks Industry Overview:

1.1 Definition of Biobanks

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Read the rest here:
R&D Activities to Fast-track the Growth of the Biobanks Market Between 2017 2025 Dagoretti News - Dagoretti News

Rheumatoid Arthritis Stem Cell Therapy Market Latest Innovations, Drivers and Industry Key Events 2018 to 2028 – Fusion Science Academy

Facial Makeup Market (2018) Report Provides an in-depth summary of Facial Makeup Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Facial Makeup Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Facial Makeup market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Facial Makeup market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Request Sample Report @https://www.mrrse.com/sample/12424?source=atm

Leading manufacturers of Facial Makeup Market:

Companies Mentioned in the Report

The report also reviews the profiles of the key companies operational in the global market for facial makeup on the basis of various attributes, such as the overview of their financial, brand, and business performance, their main business strategies, offerings, and the recent developments. The leading companies reviewed in this research report are P&G, Shiseido, LVMH, LOreal, Coty, Lakm, Estee Lauder, Avon, Revlon, and Chanel.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/12424?source=atm

Scope of The Facial Makeup Market Report:

This research report for Facial Makeup Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Facial Makeup market. The Facial Makeup Market Report analyzes opportunities in the overall Facial Makeup market for stakeholders by identifying the high-growth segments.

A detailed overview of the geographical and competitive sphere of the Facial Makeup market:

Buy This Report @ https://www.mrrse.com/checkout/12424?source=atm

Table of Content of The Report

Chapter 1- Facial Makeup Industry Overview:

1.1 Definition of Facial Makeup

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Read more:
Rheumatoid Arthritis Stem Cell Therapy Market Latest Innovations, Drivers and Industry Key Events 2018 to 2028 - Fusion Science Academy

Heart Cell Research Leads to Discovery That May Lead to Unreliable Data – Newswise

MEDIA CONTACT

Available for logged-in reporters only

American Journal of PhysiologyCell Physiology

Research Results

MEDICINE

Newswise Rockville, Md. (January 16, 2020)Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data. The study is published ahead of print in the American Journal of PhysiologyCell Physiology and was chosen as an APSselect article for January.

Fluorescence recovery after photobleaching (FRAP) is a technique that uses fluorescent microscopy to determine the amount and rate of protein movement in a cell or region of a cell. Scientists using FRAP mark a part of a cell with a fluorescent protein tag and take time-lapse images to capture the cells fluorescent protein signal. Then, they use a high-power laser that removes the proteins fluorescence in a process called photobleaching. The final phase of FRAP is recovery: the cell begins to emit fluorescence again when new fluorescent proteins are produced or transported within the cell.

One important principle in FRAP is the assumption that photobleaching is irreversible, as the [laser] disrupts the fluorescence protein structure and function, explains Adrian Cadar, PhD, first author of the study.

Researchers performed FRAPusing a fluorescent protein called mEos3.2on beating human heart cells to learn more about the turnover of titin. Titin is a very large, elastic protein that forms a complex molecular framework of muscle cells called the sarcomere. Previous research has found that the sarcomere is a dynamic structure in which there is a constant and rapid exchange of titin molecules. However, in the current study, titin tagged with mEos3.2 had a much quicker recovery time than the research team had anticipated. To determine if the recovery signal was indeed due to titin movement, the team performed a critical control by treating the cells with paraformaldehydea process called fixation. The fixation process crosslinks the proteins within the cell together, thus immobilizing them. The researchers then performed FRAP in these fixed cells, which surprisingly revealed a fluorescence recovery signal similar to the initial live cell measurements. The researchers discovered that, unlike other proteins used in FRAP, mEos3.2 refolds or restructures itself to regain fluorescence. This reversibility leads to unreliable data.

When using fluorescent proteins for FRAP studies, it is important that one validates the photo-properties of their particular fluorescent protein. In our case, the mEos3.2 photoconvertible fluorescent protein displayed a significant reversible photobleaching property which hasnt been described before. This property makes the mEos3.2 fluorescent protein an inappropriate tool for FRAP studies as the reversible photobleaching led to an overestimation of the fluorescent recovery signal, Cadar wrote.

Read the full article, Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes, published ahead of print in the American Journal of PhysiologyCell Physiology. It is highlighted as one of this months best of the best as part of the American Physiological Societys APSselect program. Read all of this months selected research articles.

NOTE TO JOURNALISTS:To schedule an interview with a member of the research team, please contact theAPS Communications Officeor call 301.634.7314. Find more research highlights in our News Room.

Physiology is the study of how molecules, cells, tissues and organs function in healthand disease.Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents nearly 10,000 members and publishes 15 peer-reviewed journals with a worldwide readership.

Original post:
Heart Cell Research Leads to Discovery That May Lead to Unreliable Data - Newswise